Live feed07:00:00·2094dPRReleasevia QuantisnowProtagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia VeraByQuantisnow·Wall Street's wire, on your screen.PTGX· Protagonist Therapeutics Inc.Health CareOriginal source
